- The European Medicines Agency (EMA) accepts for review Mylan N.V.'s (MYL +0.7%) Marketing Authorization Application (MAA) seeking approval of its insulin glargine, a long-acting insulin analog used to treat adult type 2 diabetics and adult and pediatric type 1 diabetics.
- Mylan co-developed the product with Bengaluru, India-based Biocon Ltd. Clinical studies showed bioequivalence to Sanofi's (SNY +1%) Lantus (insulin glargine injection 100 Units/mL).